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Introduction
Gastroenteropancreatic neuroendocrine tumours (GEP-
NETs) are rare neoplasms that arise from neuroendocrine
cells scattered diffusely in gastrointestinal tract as well as
endocrine cells embedded in pancreas.1 These tumours are
characterized by a varied and wide spectrum of clinical
behaviour, encompassing a well differentiated, indolent
tumour to highly malignant, rapidly metastasizing poorly
differentiated malignancy.2
The clinical presentation of patients with GEP-NETs is
dependent on functional status of the tumour. The non-
functioning tumours are more common and their
symptoms surface due to local mass effect or distant
metastasis, which includes abdominal pain, intra-
abdominal mass, weight loss, jaundice etc. Patients with
functioning tumours are mostly seen in pancreas where
symptoms become apparent by release of specific
hormones by the tumour.3
The nomenclature of neuroendocrine tumours (NET) is
generally based on the organ in focus. However, a uniform
classification has matured for NET of
gastroenteropancreatic region by World Health
Organization (WHO)4 According to WHO, GEP-NETs are
generally categorized into two broad groups:
1. Well differentiated neuroendocrine tumour (WDNET)
demonstrates a characteristic architecture on histology
that includes trabeculae, nests, glandular formation,
gyriform, pseudorosettes and solid etc. Historically they
were referred to as carcinoid tumours, but due to their
apparent confusion with clinically functional tumours,
this name is now not in use anymore.5
2. Neuroendocrine carcinoma (NEC), which includes large
cell neuroendocrine carcinoma (LCNEC) and small cell
neuroendocrine carcinoma (SCNEC) show
undifferentiated or high grade histology on light
microscopy and a poor clinical course.6
The 2010 WHO grading scheme of GEP-NET was solely
based on proliferative index (mitotic count and/or Ki-67
index), thus dividing NET into three grades. Grade I (<2%
Ki-67 index) and grade 2 (3% to 20% Ki67 index) were
consistent with WDNET, while all grade 3 NET (>20% Ki67
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index) irrespective of histological architecture were
incorporated into NEC.7 A recent modification in the said
classification has incorporated tumour architecture along
with mitotic rate for grading of these tumours. This
modification has followed various studies, which reported
high grade NET with raised mitotic index (>20%Ki-67 index)
but architectural differentiation favouring NET. These
tumours are reported to behave better in terms of survival
when compared with NEC but have a more dismal
prognosis than grade 2 WDNET.  Thus grade 3 NET are now
divided into 2: WDNET grade 3 (characteristic architectural
features and a Ki-67 index more than 20%) and NEC
(undifferentiated pattern with a Ki-67 index more than
20%).2,8
Although they are rare tumours but their prevalence has
increased substantially over past three decades, possibly
due to increased awareness and advanced diagnostic
modalities. The age-adjusted incidence of GEP-NETs has
increased 3.65-fold in the USA and 3.8- to 4.8-fold in the
UK.9 In Pakistan, data regarding incidence of
neuroendocrine tumours is not readily available. In 2016,
the Aga Khan University Hospital reported neuroendocrine
differentiation in 2.5% of the total GI malignancies while
annual cancer registry of SKMCH showed this figure to be
5.2%.10,11
Increased research regarding neuroendocrine tumours has
led to improved and newer treatment strategies and
constant update on histopathological diagnosis. Since
recent modification in WHO 2010 classification fewer
studies have reported its application. The objective of this
retrospective study was to share our analysis of GEP-NETs
at Shifa International Hospital, Pakistan according to new
WHO classification.4
Materials and Methods
The data of Shifa International Hospital, Islamabad was
retrospectively analysed for GEP-NETs after approval from
Institutional review board and ethics committee of Shifa
International Hospital, from January 2013 to March 2018.
All patients diagnosed with WDNET, NEC, SCNEC, LCNEC
from gastrointestinal tract and functional and non-
functional endocrine tumours of pancreas were included.
Epithelial tumours and metastatic NET to
gastroenteropancreatic region were excluded. 
The clinicopathological characteristics of patients noted
from their medical records included: age, gender, and
primary location of tumour, functional status of tumour,
histological type and grade of tumour, distant metastasis
and immunohistochemical status. The histological type and
tumour grade were assigned according to the new WHO
2010 classification and Union for International Cancer
Control (UICC)11 of American Joint Committee on Cancer.
According to this classification, a WDNET showing a
characteristic histological features were assigned three
grades as follows: grade 1 with a mitotic count of <2 per 10
high power fields (HPF) and/or a Ki-67 index <2%; grade 2,
with a mitotic count of 2 to 20 per 10 HPF and/or a Ki-67
index of 3 to 20%; and grade 3, with a mitotic count of >20
per 10 HPF and/or a Ki-67 index >20%. Tumours that were
high grade, showing an undifferentiated pattern, with a
mitotic account of more >20 per 10 HPF and/or a Ki-67
index >20%, and showed positivity for neuroendocrine
markers were diagnosed as NEC. High grade tumours with
a small cell size showing hyperchromatic, indistinct nucleoli
and nuclear moulding were diagnosed as SCNEC. The
mixed adenoneuroendocrine carcinomas (MANEC)
consisted of both components of adenocarcinoma and
neuroendocrine tumour, and each comprising of more
than 30 percent of the tumour population.
Results
Analysis of our data from January 2013 to March 2018
revealed 118 GEP-NETs. Fifteen patients diagnosed with
metastatic neuroendocrine tumour on liver biopsies were
excluded from the study since their primary site biopsies
could not be retrieved. The mean age of patients at the
time of diagnosis was 52.2 ±16.4 years (age range: 8-78
years) with a slight predominance of males (n= 65, 55.1%
versus females n= 53, 44.9%) and a male to female ratio of
1.2:1. The maximum patients, 32(27.1%) were in 6th decade
of life followed by 7th decade (n=26, 22%) and 5th decade
(n= 22, 18.6%). Only 20(16.9%) patients had an incidental
NET, while 98 (83.1%) symptomatic patients had different
abdominal complaints in the form of pain, mass lesion or
obstructive jaundice. Functional tumour was identified in
6(5.1%) patients encompassing 4 insulinomas and 2
gastrinomas. Pancreas,33(28%)patients, was the most
frequent primary site noted followed by stomach in17
(14.4%) (Table 1). Also pancreas and colonic tumours were
more common in males while duodenal tumours in
10(71%) patients were commonly seen in females.
Duodenal tumours were encountered mostly in the 6th
decade, while tumours in appendix were diagnosed in a
younger age group (20-40 years).
The most common histologic type was WDNET in 96
(81.4%) cases, followed by NEC in 19(16.1%) cases that
included Neuroendocrine carcinoma not otherwise
specified (NEC-NOS) in 11 (57.8%), SCNEC in 7 (36.8%),
1(5.2%) case of  LCNEC (Table 2) and 3 cases (2.5%) were
MANEC.
Almost half, 54 (45.8%) cases of WDNET were grade 1, 32
(27.1%) cases were grade 2, and 10 (8.5%) cases were 
grade 3.
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Low grade WDNET (grade 1 & 2) were frequently localized
in pancreas (n= 26), stomach (n=12) and rectum (n= 6)
while majority of the grade 3 WDNET had their primaries in
colon (n= 4). NEC were more common in pancreas (n= 5)
and stomach (n= 3) while SCNEC were more common in
oesophagus, 5 patients. Distant metastasis at the time of
diagnosis was encountered in 18(15.3%) patients which
included 13.6% of grade 1 & 2, 20% of grade 3 and 21% of
NEC. The most common site of metastasis was liver in
14(77.7%) patients, while 4 cases had abdominal wall and
lung metastasis. Pancreas was the most frequent primary
site of the tumour that showed distant metastasis, seen in
12(66.6%) cases. Only 6 (5.0%) patients displayed
synchronous tumours that included 4 adenocarcinomas of
stomach and 2 hepatocellular carcinoma.
Synaptophysin and chromogranin were the most
commonly applied immunohistochemical markers for
confirmation of neuroendocrine differentiation. Out of 67
cases, in which both of these markers were applied, only 1
case was negative for both of them. In this case, CD56 was
helpful in confirming the diagnosis. Synaptophysin was
positive in 60(96.8%) patients  which was the majority of
the NET of G1 & G2 WDNET. There were 8(100%)cases of G3
WDNET and 12(92.3%) of NEC.
Chromogranin also had a similar pattern of positivity in
49(94.2%) of G1 and G2 WDNET, and G3 WDNET was seen
in 5(83.3%) and 5(45.4%) of NEC.
Discussion
Neuroendocrine tumours are rare malignancies whose
behaviour is dependent on the level of differentiation,
proliferative indices and extent of invasion. Therefore,
segregation of WDNET category from NEC not only imparts
prognostic stratification but also ascertains therapeutic
decision.12 Utilizing special techniques like molecular
analysis and immunohistochemistry aids in this division
but morphological features have a major implication.13,14
The mean age at diagnosis for patients of GEP-NET was
52.2±16.4 years with 6th decade of life (27.1%) as the most
common age group noted. Males (55.1%) have a slightly
higher frequency of involvement than females (44.9%). The
regional studies in different countries of Asia have similar
peak age group at diagnosis. A nationwide retrospective
analysis of GEP-NETs in China showed 50-60 years as peak
age group with a male to female ratio of 1.4:1.15 Joseph et
al also found 41-60 year as the most commonly involved
age range for GEP-NET in the Indian population. However,
their male to female ratio was 2.7:1, slightly higher when
compared to the Pakistani population (1.2:1).16 Asian
population is generally noted to have a younger age at
diagnosis compared to Americans (53.0 years vs 63.0
years).17
Most (83.1%) of the patients diagnosed with GEP-NETs
were symptomatic unlike those reported by Lim et al who
had 73.4% patients asymptomatic.18 The 8 patients
frequently had complaints related to tumour mass effect in
the form of abdominal pain, discomfort and a palpable
abdominal mass. Only 19(16.9%)  patients did not have
symptoms related to neuroendocrine tumour and they
were discovered accidently either on routine examination
or excision biopsy done for some other disease. The
predominant site for these asymptomatic tumours was
appendix (n= 11) followed by duodenum (n = 3). 
Out of total 118 cases, 6(5.1%) tumours were functional
that included 4 insulinomas and 2 gastrinomas, with 5 of
them having their primaries in the pancreas. This compares
with a study done in a local population of Turkey where
retrospective analysis of 42 cases of GEP-NETs showed 4.8%
functional NET.19
A significant load of GEP-NET was noted in the pancreas
(28%) followed by the stomach (14.4%) as shown in 
table 1. The primary location of GEP-NETs has shown a
diverse regional variability. A single centre study from
Korea found duodenum as the most common primary
Table-2: Histological type and grade according to 2010 WHO classification.
Histological type & grade n (%)
Well differentiated neuroendocrine tumour 96 (81.4)
Grade I 54 (45.8)
Grade II 32 (27.1)
Grade III 10 (8.5)
Neuroendocrine carcinoma 19 (16.1)
NEC- Unclassified 11 (57.8)
Small cell carcinoma 7 (36.8)
Large cell carcinoma 1 (5.2)
Mixed adenoneuroendocrine 3 (2.5)
Table-1: Primary site of neuroendocrine tumours.
Tumor site n (%)






Ileocaecal junction 2 (1.7)
Ileum 5 (4.2) 
Jejunum 3 (2.5)
Pancreas 33 (28.0)
Periampullary region 8 (6.8)
Rectum 7 (5.9)
Stomach 17 (14.4)
location, whereas pancreas and rectum were the most
frequent primary location observed in China.15,18,20
Buyukasik et al reported stomach as the most common site
in his research in a hospital of Turkey.19 Also published data
from western countries have frequently shown small
intestine as the most common primary site.18,21
The most frequent histological type was WDNET in 81.4%
of the cases, followed by NEC in 16.0% (Table 2). Wang et
al reported WDNET in 70.3% of the cases; however, NEC
constituted 29.0%, which is higher than our population. It
could be due to the reason that all grade 3 tumours (grade
3 WDNET and NEC) were included in this category. Manec
had 0.7% in his study, slightly lower as compared to our
population (2.5%).22
With the modification in WHO grading of GEP-NET more
and more researches are now focusing on grade 3 WDNET.
Although there is sufficient data available on
neuroendocrine tumours but studies quoting grade III
WDNET are limited. They have usually been reported in the
range of 9-16% in literature.20 We found 8.5% grade 3
WDNET, which is slightly lower than that reported. An
Italian multicentre retrospective study identified 17.6% of
the cases previously diagnosed as NEC, as WDNET grade 3
and majority of them were located in the pancreas,22 while
a single institutional experience in India showed 12.5%
grade 3 WDNET.23 However, researchers who have studied
both NET and NEC have reported more grade 3 WDNET
compared to NEC unlike our data (9.3% versus 16.9%).22
Grade 1 and 2 WDNET were predominantly seen in the
pancreas (n=26) while grade 3 WDNET was more common
in the colon (n=4), however, they were also seen in the
stomach (n= 2), pancreas (n=2), duodenum (n=1) and
oesophagus (n=1). Pancreas was also the most frequently
involved site for NEC-unclassified (n=5) and LCNEC.24,25 Low
grade WDNET has commonly been reported in appendix,
stomach and duodenum, while pancreas is a site common
for grade 3 tumours as reported by various studies.19,26
Whereas our observed data of Pakistan signifies that
although pancreas is a common site for both low and high
grade NET, but grade 3 WDNET have been found to be
associated with colon more frequently.
Metastatic disease was evident in 15.3% cases at the time
of diagnosis, which increased with the grade of the tumour
(11.9% of low grade, 20% of grade 3 WDNET and 21% of
NEC). The most common metastatic site was liver (11.9%)
and 4 cases metastasized to abdominal wall (n=3) and lung
(n=1). Pancreas (36.3%) was the most frequent primary site
of tumour that showed distant metastasis. Lim et al have
reported 8.9% GEP-NET with distant metastasis with liver
as the most common site.18 However, Yao et al have
reported a much higher percentage of NET with metastatic
disease. According to him, 21% of G1, 30% of G2 and 50%
of poorly differentiated (G3) tumours or undifferentiated
(G4) tumours had synchronous distant metastasis at
diagnosis, which is much higher in comparison to Pakistani
population.26 Only 5% patients showed synchronous
tumours that included 4 adenocarcinomas of stomach and
2 hepatocellular carcinoma. Kamp et al studied 459 GEP-
NETs and found 2.8% had a synchronous tumour.27
A high positivity of synaptophysin was noted in all grades
of GEP-NET. Chromogranin positivity however decreased
with grade and differentiation of the tumour. This is in
comparison to a study reported by Buyukasik et al, who
found chromogranin A and synaptophysin positivity in
78.8% and 90.3% of gastroenteropancreatic NET,
respectively, regardless of the grade 19. Wang et al studied
chromogranin expression on 145 GEP-NET and they found
66% positivity in NET and 78% in NEC.22
Conclusion
GPNET has been found at various anatomic locations in
gastrointestinal tract and pancreas with a wide variety of
clinical presentation. Pancreas is the most commonly
involved site by low as well as high grade NET tumours,
while grade 3 WDNET had a predilection for colon.
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